ArticleFrontiers in pediatrics2026
Case Report: Managing coagulopathy in neonatal acute liver failure: insights from a case of rebalanced hemostasis and thromboelastography monitoring.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal acute liver failure (ALF) is a rare, life-threatening condition often accompanied by complex coagulopathy. Managing this coagulopathy is challenging due to the limitations of conventional coagulation tests and the lack of pediatric-specific transfusion guidelines, often leading to empiric blood product use. Methods: We present a detailed case report of a neonate with ALF of indeterminate etiology. Clinical and laboratory monitoring included serial conventional coagulation tests (PT, APTT, INR, fibrinogen, D-dimer), coagulation factor assays, and thromboelastography (TEG). The therapeutic management and response to blood product transfusions (fresh frozen plasma, cryoprecipitate, platelets) were documented over a one-month hospitalization. Results: The patient exhibited severe and persistent abnormalities in standard coagulation parameters (prolonged PT/APTT, elevated INR, hypofibrinogenemia, and deficiency of factors II, V, VII, IX-XII, ATIII, PC, PS) alongside thrombocytopenia. In contrast, TEG revealed a normal reaction (R) time, but a reduced alpha-angle and maximum amplitude (MA). Despite 14 transfusions of fresh frozen plasma, conventional coagulation parameters showed minimal improvement. Conclusion: This case illustrates the complexity of coagulation monitoring in neonatal liver failure. It underscores the significance of comprehensive global hemostasis assays, such as TEG, which may provide superior guidance for transfusion therapy and help prevent the unnecessary administration of blood products in non-bleeding neonates with ALF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.